PatientsVille.com Logo


Eprex Medical Research Studies

Up-to-date List of Eprex Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Eprex Medical Research Studies

Rank Status Study
1 Unknown  Mifepristone 10 or 5 mg for 6 Months to Treat Uterine Fibroids
Condition: Uterine Fibroids
Intervention: Drug: Mifepristone
Outcome Measures: Volume of the uterine leiomyomata with 5 versus 10 mg of mifepristone daily after six months of treatment;   Prevalence of symptoms after 6 months treatment with 5 or 10 mg of mifepristone.
2 Recruiting Pre-Operative Effects of Mifepristone on Dilation and Evacuation Services
Condition: Legally Induced Abortion Without Mention of Complication
Interventions: Other: Hygroscopic cervical dilators;   Drug: Misoprostol;   Drug: Intra-amniotic digoxin;   Drug: Mifepristone
Outcome Measures: Procedure Time;   Total Procedure Time;   Maximum Cervical Dilation;   Adverse Events;   Ease of Procedure by Blinded Surgeon;   Pain Perceived by Patient;   Overall patient experience
3 Recruiting Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: enzalutamide;   Drug: mifepristone;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: Recommended phase II dose defined as the highest mifepristone dose in combination with enzalutamide such that < 33% experience dose-limiting toxicity graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Phase I);   PSA progression-free survival (PFS) defined as a PSA (confirmed 2 weeks later) that is >= 1.25 times (25% increase) the PSA at randomization (week 12) (Phase II);   Overall survival (Phase II);   Radiographic PFS (Phase II);   Pharmacokinetic (PK) parameters of enzalutamide and mifepristone;   AR expression within circulating tumor cells (CTCs);   GR expression within CTCs
4 Recruiting Mifepristone Versus Misoprostol for Cervical Preparation Prior to Surgical Abortion Between 11 to 15 Weeks
Conditions: Induced Abortion;   Abortion Techniques;   Mifepristone;   Misoprostol
Interventions: Drug: Mifepristone;   Drug: Misoprostol
Outcome Measures: Initial cervical dilation at the time of surgical abortion;   Additional cervical dilation required to complete abortion procedure;   Time to conduct procedure;   Percentage of patients who report nausea, vomiting, diarrhea, and vaginal bleeding;   Preoperative, intraoperative, and postoperative pain score;   Surgeon's difficulty rating of procedure;   Complications of procedure
5 Recruiting Exploring a Patient-centered Approach to Mifepristone Administration in Medical Abortion
Condition: Termination of Pregnancy
Intervention: Drug: Mifepristone
Outcome Measures: Proportion of participants who would choose outside of center administration of mifepristone again;   Proportion of participants who would recommend outside-of-center administration to a friend;   Proportion of women who select outside-of-clinic use of mifepristone;   Success Rates/Method Failure;   Adherence;   Provider-related outcomes
6 Recruiting Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: mifepristone;   Drug: carboplatin;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: MTD/RP2D, defined as < 1/6 patients at highest dose level below max administered dose or fewer than 33% of patients experiencing dose limiting toxicity (DLT), graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0;   Response to treatment according to Response Evaluation Criteria in Solid Tumors 1.1;   Progression free survival (PFS);   OS
7 Recruiting Novel Therapeutics in Posttraumatic Stress Disorder (PTSD): A Randomized Clinical Trial of Mifepristone
Condition: Stress Disorders, Post-Traumatic
Intervention: Drug: Mifepristone (600 mg/day) or placebo (sugar pill)
Outcome Measures: Presence or absence of a clinical response, defined as a 30% or greater reduction in total CAPS (past week symptom status);   Changes in CAPS (past week symptom status) score from baseline to weeks 1, 4, and 12 to capture time by treatment interaction, the proportion of clinical responders at 12 weeks for deciding sustainability, the time to addition of rescue medication to det
8 Recruiting Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism
Condition: Mild Hypercortisolism
Intervention: Drug: Mifepristone
Outcome Measures: hyperglycemia;   Metabolic Syndrome;   Quality of Life
9 Recruiting Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Mifepristone and Eribulin in combination
Outcome Measure: Determine the maximum tolerated dose (MTD) of the combination of mifepristone and eribulin in patients with metastatic or locally advanced unresectable triple negative breast cancer (TNBC).
10 Recruiting Mifepristone in Children With Refractory Cushing's Disease
Condition: Cushing's Disease
Intervention: Drug: mifepristone
Outcome Measure: Adverse events
11 Recruiting Developing Memory Reconsolidation Blockers as Novel Post-traumatic Stress Disorder (PTSD) Treatments
Condition: Post-traumatic Stress Disorder
Interventions: Drug: Mifepristone;   Drug: Cycloserine;   Drug: sugar pill
Outcome Measure: Psychophysiologic Responses during script-driven imagery of traumatic events
12 Recruiting Introducing Mifepristone-Misoprostol for Menstrual Regulation in Public Sector Facilities in Bangladesh
Condition: Menstrual Regulation
Intervention: Drug: Mifepristone and misoprostol
Outcome Measure: successful menstrual regulation without the need for a surgical evacuation
13 Recruiting Medication Enhanced Rapid Therapy
Condition: Anxiety Disorders
Intervention: Drug: d-cycloserine and mifepristone
Outcome Measures: Will measure medication tolerability and safety per participant report (i.e. few or no side effects severe enough to stop treatment);   Improvements in Anxiety as measured by several Self Report Assessments;   Level of Anxiety as measured by several Self Report Assessments
14 Recruiting A Randomized Clinical Trial of Mifepristone in PTSD
Condition: PTSD
Interventions: Drug: 600 mg/day Mifepristone;   Drug: Placebo
Outcome Measure: CAPS score
15 Recruiting Effects of Mifepristone on Biomarkers of Metabolic Function and Neuropsychological Performance Among Middle-Aged and Older Individuals
Condition: Depression
Intervention: Drug: 28 days treatment with Mifepristone.
Outcome Measures: Cognition;   Hamilton Score
16 Recruiting Mifepristone and Misoprostol for the Termination of Pregnancy up to 70 Days' Gestation in Kazakhstan
Condition: Complete Abortion
Intervention: Drug: Mifepristone, misoprostol
Outcome Measures: Rate of successful abortion;   Satisfaction with method
17 Recruiting Mifepristone for Metabolic Syndrome
Conditions: Endocrine Disease;   Diabetes
Intervention: Drug: Mifepristone
Outcome Measures: To change in insulin sensitivity index based on the effect of insulin on glucose during frequently sampled IV glucose tolerance test (FSIVGTT);   Whole-body rate of regenerating cortisol response to mifepristone of glucose insulin sensitivity, free fatty acid clearance, cortisol metabolites, adrenal hormones.
18 Recruiting Pretreatment With Mifepristone Prior to Mirena Insertion
Condition: Women in Need of Long Acting Reversibel Cntraception With the Intrauterine Levonorgestrel Releasing System, Mirena
Interventions: Drug: Mifepristone prior to Mirena;   Drug: Placebo prior to Mirena insertion
Outcome Measures: Days with bleeding and spotting;   Endometrial changes;   Effects on breast tissue
19 Recruiting Medication Development in Alcoholism: Investigating Glucocorticoid Antagonists
Condition: Alcoholism
Interventions: Drug: Korlym (mifepristone);   Drug: Sugar Pill
Outcome Measures: Craving to Drink;   Drinking
20 Not yet recruiting BRCA1/2 and Effect of Mifepristone on the Breast
Condition: Women With Mutations in the Breast Cancer Susceptibility Genes BRCA-1 and -2.
Intervention: Drug: Mifepristone
Outcome Measures: epithelial cell proliferation in breast tissue;   Vital signs and safety lab analysis;   Side effects and Adverse Events;   Endometrial effects;   Ovarian effects;   Breast symptom evaluation

These studies may lead to new treatments and are adding insight into Eprex etiology and treatment.

A major focus of Eprex research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Eprex